Circulating tumor DNA as a biomarker for the prediction of minimal residual disease and the individualization of adjuvant therapy in colorectal cancer – a review of current evidence and perspectives
Klinicka onkologie · 15.04.2026 · 39 (2) · 105-111
DOI: 10.48095/ccko2026105 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Klinicka onkologie, online erschienen am 15.04.2026. Verfasst von A Pirshtuk und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA, Neoplasm, Residual, Biomarkers, Tumor.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Pirshtuk, A., Büchler, T., & Vymetálková, V. (2026). Circulating tumor DNA as a biomarker for the prediction of minimal residual disease and the individualization of adjuvant therapy in colorectal cancer – a review of current evidence and perspectives. Klinicka onkologie, 39(2), 105-111. https://doi.org/10.48095/ccko2026105
Vancouver
Pirshtuk A, Büchler T, Vymetálková V. Circulating tumor DNA as a biomarker for the prediction of minimal residual disease and the individualization of adjuvant therapy in colorectal cancer – a review of current evidence and perspectives. Klinicka onkologie. 2026;39(2):105-111. doi:10.48095/ccko2026105
BibTeX
@article{Pirshtuk2026,
author = {Pirshtuk, A and Büchler, T and Vymetálková, V},
title = {Circulating tumor DNA as a biomarker for the prediction of minimal residual disease and the individualization of adjuvant therapy in colorectal cancer – a review of current evidence and perspectives},
journal = {Klinicka onkologie},
year = {2026},
volume = {39},
number = {2},
pages = {105--111},
doi = {10.48095/ccko2026105}
}
EUVIMED